Gene genie for AMD and RP?

Retinitis pigmentosa and AMD may be the beneficiaries of a new tool for gene therapy that significantly increases gene delivery to cells in the retina.

Retinitis pigmentosa and AMD may be the beneficiaries of a new tool for gene therapy that significantly increases gene delivery to cells in the retina.

In news reports, including Science Daily, senior author Rajendra Kumar-Singh, PhD, associate professor of ophthalmology and adjunct associate professor of neuroscience at Tufts University School of Medicine (TUSM) and member of the genetics; neuroscience; and cell, molecular, and developmental biology program faculties at the Sackler School of Graduate Biomedical Sciences at Tufts said: “For the first time, we have demonstrated an efficient way to transfer DNA into cells without using a virus, currently the most common means of DNA delivery. Many non-viral vectors for gene therapy have been developed but few, if any, work in post-mitotic tissues such as the retina and brain. Identifying effective carriers like PEG-POD brings us closer to gene therapy to protect the retinal cells from degeneration.” The research is published in The Journal of Gene Medicine.

Related Videos
Fluid dynamics in wet macular degeneration: How fluid type affects visual acuity
EURETINA leadership discusses what to expect at the 2022 Congress, outlines Women in Retina programme
Paediatric eyes repair better with scleral buckling, adults need vitrectomy only for giant retinal tear-related detachments
Related Content
© 2023 MJH Life Sciences

All rights reserved.